Formulations That Meet Unmet Patient Needs
Focused on long acting
Developing Finished Dosage Forms and a Portfolio of APIs
Fully integrated GMP
Pipeline of Multiple Late Stage Products
In Phase III for RMS and Phase II for
PPMS for treating MS
We are a clinical stage pharmaceutical company, developing complex active pharmaceutical ingredients.
Our main focus is on developing long acting depot injectable drugs.
Our lead programs are GA Depot for treating various forms of MS and long acting Pregabalin (Lyrica®) for pain.
Mapi Pharma Announces Positive Top-Line Results from GA Depot Phase III Trial for Relapsing forms of Multiple Sclerosis (RMS)
The study evaluating a long-acting glatiramer acetate injection, GA Depot 40 mg once every four weeks, met the primary endpoint, significantly reducing the annualized relapse rate (ARR) by 30.1 percent compared to placebo NESS ZIONA, Israel – Sep. 21, 2022 – Mapi...
Mapi Pharma to Present Late Breaking Poster Presentation on GA Depot for Treating Primary Progressive Forms of Multiple Sclerosis at CMSC 2022 Annual Meeting
Interim analysis of Phase IIa study of GA Depot in PPMS will be presented NESS ZIONA, Israel – May 31, 2022 – Mapi Pharma Ltd., a fully integrated, late-stage clinical development biopharmaceutical company focused on introducing innovative long-acting depot injectable...